Skip to content
lifestyle.floredechampagne.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Harbour Biomed
TSLP Antibody Asthma: Positive Phase 2 Results for HBM9378/WIN378, Phase 3 Initiated
September 8, 2026
Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition
September 6, 2026
Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
August 27, 2026
Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
August 27, 2026
Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
August 20, 2026
Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies
August 19, 2026
Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium
August 18, 2026
Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
August 18, 2026
Harbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate
May 17, 2026
Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors
May 8, 2026
1
2
Next Page
→